Another milestone achieved for Roboderm® technology in the US market
We are excited to announce that the US Food and Drug Administration (FDA) has cleared laser devices in the new icoone range. This additional authorisation for our Roboderm technology marks another step forward in icoone's path to commercialisation in the US market.
The latest generation of icoone microstimulators, with a +25% increase in active stimulation surface area, introduces an innovative approach to reducing the appearance of cellulite, improving blood circulation and relieving pain and muscle spasms. In addition, microstimulations in combination with LED (with a wavelength of 650 nm) and Laser (with a wavelength of 950 nm) help to achieve faster results and make them last longer.
A host of other new features, including additional handpieces, a more intuitive user interface and new programmes, will now provide doctors and cosmetic practitioners with state-of-the-art, non-invasive technology for even more personalised treatments, uniquely designed for a comfortable and relaxing customer/patient experience.
Luca Gualdrini, General Manager of i-Tech, states "We are proud to have reached this new milestone. It marks the next step in our worldwide distribution plans and we are looking forward to presenting the new range to our customers so that they can experience a technology whose main objective is to deliver results.
